| Title |
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
|
|---|---|
| Published in |
Diabetes Therapy, July 2018
|
| DOI | 10.1007/s13300-018-0471-8 |
| Pubmed ID | |
| Authors |
John Wilding, Kevin Fernando, Nicola Milne, Marc Evans, Amar Ali, Steve Bain, Debbie Hicks, June James, Philip Newland-Jones, Dipesh Patel, Adie Viljoen |
| Abstract |
Management of type 2 diabetes mellitus (T2DM) is complex and challenging, particularly for clinicians working in primary care who are faced with many competing clinical priorities. The range of available T2DM treatments has diversified significantly in recent years, generating a busy and data-rich environment in which evidence is rapidly evolving. Sodium-glucose cotransporter-2 inhibitor (SGLT2i) agents are a relatively new class of oral glucose-lowering therapy that have been available in the UK for approximately 5 years. These agents reduce the reabsorption of glucose in the kidney and increase its excretion via the urine. Conflicting messages and opinions within the clinical community have led to misconceptions concerning the efficacy, safety and appropriate position of SGLT2i therapies within the T2DM treatment pathway. To help address some of these concerns and provide advice regarding the appropriate place of these medicines in clinical practice, the Improving Diabetes Steering Committee was formed. The Committee worked together to develop this review article, providing a summary of relevant data regarding the use of SGLT2i medicines and focusing on specific considerations for appropriate prescribing within the T2DM management pathway. In addition, a benefit/risk tool has been provided (see Fig. 3) that summarises many of the aspects discussed in this review. The tool aims to support clinicians in identifying the people most likely to benefit from SGLT2i treatments, as well as situations where caution may be required. Napp Pharmaceuticals Limited. |
X Demographics
The data shown below were collected from the profiles of 79 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 44 | 56% |
| United States | 4 | 5% |
| Netherlands | 2 | 3% |
| Ireland | 2 | 3% |
| India | 2 | 3% |
| Cyprus | 1 | 1% |
| Malta | 1 | 1% |
| Turkey | 1 | 1% |
| Australia | 1 | 1% |
| Other | 1 | 1% |
| Unknown | 20 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 45 | 57% |
| Practitioners (doctors, other healthcare professionals) | 26 | 33% |
| Scientists | 5 | 6% |
| Science communicators (journalists, bloggers, editors) | 3 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 123 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 13% |
| Student > Bachelor | 16 | 13% |
| Student > Ph. D. Student | 8 | 7% |
| Student > Postgraduate | 8 | 7% |
| Student > Master | 8 | 7% |
| Other | 23 | 19% |
| Unknown | 44 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 11% |
| Nursing and Health Professions | 5 | 4% |
| Agricultural and Biological Sciences | 3 | 2% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Other | 15 | 12% |
| Unknown | 45 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 57. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2020.
All research outputs
#733,299
of 25,123,315 outputs
Outputs from Diabetes Therapy
#28
of 1,133 outputs
Outputs of similar age
#15,745
of 335,869 outputs
Outputs of similar age from Diabetes Therapy
#1
of 21 outputs
Altmetric has tracked 25,123,315 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,133 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,869 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.